Merrimack Pharma Reports Completion Of Strategic Review, Will Implement Series Of Measures To Extend Co.'s Cash Runway Into 2027; 100 Potential Partners Were Contacted, Co. Will Not Move Forward With Any Of Them
Benzinga Newsdesk